Annals of Coloproctology

Review

Colorectal cancer

Performance reporting design in artificial intelligence studies using image-based TNM staging and prognostic parameters in rectal cancer: a systematic review: Minsung Kim, Taeyong Park, Bo Young Oh, Min Jeong Kim, Bum-Joo Cho, Il Tae Son; Ann Coloproctol. 2024;40(1):13-26. Published online February 28, 2024; DOI: https://doi.org/10.3393/ac.2023.00892.0127

3,134 View
178 Download
4 Web of Science
5 Citations

Purpose
The integration of artificial intelligence (AI) and magnetic resonance imaging in rectal cancer has the potential to enhance diagnostic accuracy by identifying subtle patterns and aiding tumor delineation and lymph node assessment. According to our systematic review focusing on convolutional neural networks, AI-driven tumor staging and the prediction of treatment response facilitate tailored treatment strategies for patients with rectal cancer.
Methods
This paper summarizes the current landscape of AI in the imaging field of rectal cancer, emphasizing the performance reporting design based on the quality of the dataset, model performance, and external validation.
Results
AI-driven tumor segmentation has demonstrated promising results using various convolutional neural network models. AI-based predictions of staging and treatment response have exhibited potential as auxiliary tools for personalized treatment strategies. Some studies have indicated superior performance than conventional models in predicting microsatellite instability and KRAS status, offering noninvasive and cost-effective alternatives for identifying genetic mutations.
Conclusion
Image-based AI studies for rectal cancer have shown acceptable diagnostic performance but face several challenges, including limited dataset sizes with standardized data, the need for multicenter studies, and the absence of oncologic relevance and external validation for clinical implantation. Overcoming these pitfalls and hurdles is essential for the feasible integration of AI models in clinical settings for rectal cancer, warranting further research.

Citations

Citations to this article as recorded by

Enhancing the role of MRI in rectal cancer: advances from staging to prognosis prediction
Xiaoling Gong, Zheng Ye, Yu Shen, Bin Song
European Radiology.2025;[Epub] CrossRef
L’intelligence artificielle pourrait-elle aider le chirurgien digestif dans la prise en charge du cancer du rectum ?
Arnaud Alves, Karem Slim
Journal de Chirurgie Viscérale.2024; 161(4): 253. CrossRef
Can artificial intelligence help a digestive surgeon in management of rectal cancer?
Arnaud Alves, Karem Slim
Journal of Visceral Surgery.2024; 161(4): 231. CrossRef
Artificial intelligence for the colorectal surgeon in 2024 – A narrative review of Prevalence, Policies, and (needed) Protections
Kurt S. Schultz, Michelle L. Hughes, Warqaa M. Akram, Anne K. Mongiu
Seminars in Colon and Rectal Surgery.2024; 35(3): 101037. CrossRef
Artificial Intelligence in Coloproctology: A Review of Emerging Technologies and Clinical Applications
Joana Mota, Maria João Almeida, Miguel Martins, Francisco Mendes, Pedro Cardoso, João Afonso, Tiago Ribeiro, João Ferreira, Filipa Fonseca, Manuel Limbert, Susana Lopes, Guilherme Macedo, Fernando Castro Poças, Miguel Mascarenhas
Journal of Clinical Medicine.2024; 13(19): 5842. CrossRef

Editorial

Malignant disease,Rectal cancer

Advances in surgery for locally advanced rectal cancer: Bo Young Oh; Ann Coloproctol. 2022;38(4):279-280. Published online August 29, 2022; DOI: https://doi.org/10.3393/ac.2022.00493.0070

2,502 View
139 Download
5 Web of Science
5 Citations

PDF

Citations

Citations to this article as recorded by

Risk factors for the failure of endoscopic balloon dilation to manage anastomotic stricture from colorectal surgery: retrospective cohort study
Young Il Kim, Seung Wook Hong, Seok-Byung Lim, Dong-Hoon Yang, Eon Bin Kim, Min Hyun Kim, Chan Wook Kim, Jong Lyul Lee, Yong Sik Yoon, In Ja Park, Chang Sik Yu
Surgical Endoscopy.2024; 38(4): 1775. CrossRef
Performance reporting design in artificial intelligence studies using image-based TNM staging and prognostic parameters in rectal cancer: a systematic review
Minsung Kim, Taeyong Park, Bo Young Oh, Min Jeong Kim, Bum-Joo Cho, Il Tae Son
Annals of Coloproctology.2024; 40(1): 13. CrossRef
Characterization and proteomic analysis of plasma-derived small extracellular vesicles in locally advanced rectal cancer patients
Haiyan Chen, Yimin Fang, Siqi Dai, Kai Jiang, Li Shen, Jian Zhao, Kanghua Huang, Xiaofeng Zhou, Kefeng Ding
Cellular Oncology.2024; 47(5): 1995. CrossRef
Unveiling the profound advantages of total neoadjuvant therapy in rectal cancer: a trailblazing exploration
Kyung Uk Jung, Hyung Ook Kim, Hungdai Kim, Donghyoun Lee, Chinock Cheong
Annals of Surgical Treatment and Research.2023; 105(6): 341. CrossRef
Recurrence Patterns and Risk Factors after Curative Resection for Colorectal Cancer: Insights for Postoperative Surveillance Strategies
Hyo Seon Ryu, Jin Kim, Ye Ryung Park, Eun Hae Cho, Jeong Min Choo, Ji-Seon Kim, Se-Jin Baek, Jung-Myun Kwak
Cancers.2023; 15(24): 5791. CrossRef

Review

Benign proctology

A systematic review of translation and experimental studies on internal anal sphincter for fecal incontinence: Minsung Kim, Bo-Young Oh, Ji-Seon Lee, Dogeon Yoon, Wook Chun, Il Tae Son; Ann Coloproctol. 2022;38(3):183-196. Published online June 9, 2022; DOI: https://doi.org/10.3393/ac.2022.00276.0039

4,134 View
151 Download
4 Web of Science
5 Citations

Abstract PDF

The complexity in the molecular mechanism of the internal anal sphincter (IAS) limits preclinical or clinical outcomes of fecal incontinence (FI) treatment. So far, there are no systematic reviews of IAS translation and experimental studies that have been reported. This systematic review aims to provide a comprehensive understanding of IAS critical role in FI. Previous studies revealed the key pathway for basal tone and relaxation of IAS in different properties as follows; calcium, Rho-associated, coiled-coil containing serine/threonine kinase, aging-associated IAS dysfunction, oxidative stress, renin-angiotensin-aldosterone, cyclooxygenase, and inhibitory neurotransmitters. Previous studies have reported improved functional outcomes of cellular treatment for regeneration of dysfunctional IAS, using various stem cells, but did not demonstrate the interrelationship between those results and basal tone or relaxation-related molecular pathway of IAS. Furthermore, these results have lower specificity for IAS-incontinence due to the included external anal sphincter or nerve injury regardless of the cell type. An acellular approach using bioengineered IAS showed a physiologic response of basal tone and relaxation response similar to human IAS. However, in both cellular and acellular approaches, the lack of human IAS data still hampers clinical application. Therefore, the IAS regeneration presents more challenges and warrants more advances.

Citations

Citations to this article as recorded by

A single-center retrospective analysis of endorectal advancement flaps used for the treatment of simple rectovaginal fistulas
Xuexiao Li, Wanjin Shao, Guidong Sun
Scandinavian Journal of Gastroenterology.2025; : 1. CrossRef
Tissue engineering and regenerative medicine approaches in colorectal surgery
Bigyan B. Mainali, James J. Yoo, Mitchell R. Ladd
Annals of Coloproctology.2024; 40(4): 336. CrossRef
3D spheroids versus 2D-cultured human adipose stem cells to generate smooth muscle cells in an internal anal sphincter-targeting cryoinjured mouse model
Iltae Son, Minsung Kim, Ji-Seon Lee, Dogeon Yoon, You-Rin Kim, Ji Hye Park, Bo-Young Oh, Wook Chun, Sung-Bum Kang
Stem Cell Research & Therapy.2024;[Epub] CrossRef
Differentiation of Adipose-Derived Stem Cells into Smooth Muscle Cells in an Internal Anal Sphincter-Targeting Anal Incontinence Rat Model
Minsung Kim, Bo-Young Oh, Ji-Seon Lee, Dogeon Yoon, You-Rin Kim, Wook Chun, Jong Wan Kim, Il Tae Son
Journal of Clinical Medicine.2023; 12(4): 1632. CrossRef
Improving Efficiency and Accuracy in English Translation Learning: Investigating a Semantic Analysis Correction Algorithm
Lingmei Cao, Junru Fu
Applied Artificial Intelligence.2023;[Epub] CrossRef

Original Articles

Malignant disease,Rectal cancer,Prognosis and adjuvant therapy,Colorectal cancer

Prognostic Impact of Carcinoembryonic Antigen Levels in Rectal Cancer Patients Who Had Received Neoadjuvant Chemoradiotherapy: Jung Il Joo, Sang Woo Lim, Bo Young Oh; Ann Coloproctol. 2021;37(3):179-185. Published online May 11, 2021; DOI: https://doi.org/10.3393/ac.2020.11.27

3,850 View
76 Download
5 Web of Science
5 Citations

Abstract PDF Supplementary Material

Purpose
Carcinoembryonic antigen (CEA) is a useful marker for rectal cancer. The aim of this study was to investigate the prognostic impact of CEA level according to neoadjuvant chemoradiotherapy (nCRT) in rectal cancer patients who underwent radical surgery.
Methods
A total of 245 patients with rectal cancer who underwent radical surgery were retrospectively evaluated. Serum CEA level was measured preoperatively and postoperatively. We compared survival outcomes based on CEA level before and after surgery according to nCRT.
Results
Of the 245 patients, elevation of CEA level was observed preoperatively in 79 and postoperatively in 30, respectively. Eighty-seven (35.5%) patients received nCRT, and elevated CEA level was a significant prognostic factor both before and after surgery. In patients who had not received nCRT, an elevated CEA level was a significant prognostic factor before surgery but was not significant after surgery. In a multivariate analysis for prognostic factors, elevation of preoperative CEA level was an independent prognostic factor of disease-free survival (DFS) regardless of nCRT. Postoperative CEA level was an independent prognostic factor of DFS in patients who had received nCRT but was not a factor in patients who had not received nCRT.
Conclusion
Serum CEA level was an independent prognostic factor both preoperatively and postoperatively in rectal cancer patients who had received nCRT.

Citations

Citations to this article as recorded by

Impact of Postoperative Naples Prognostic Score to Predict Survival in Patients with Stage II–III Colorectal Cancer
Su Hyeong Park, Hye Seung Woo, In Kyung Hong, Eun Jung Park
Cancers.2023; 15(20): 5098. CrossRef
Unveiling the profound advantages of total neoadjuvant therapy in rectal cancer: a trailblazing exploration
Kyung Uk Jung, Hyung Ook Kim, Hungdai Kim, Donghyoun Lee, Chinock Cheong
Annals of Surgical Treatment and Research.2023; 105(6): 341. CrossRef
Inflammatory Response Markers as Predictors of Colorectal Cancer Prognosis
Minsung Kim, Il Tae Son, Bo Young Oh
The Ewha Medical Journal.2023;[Epub] CrossRef
Prognostic Impact of An Integrative Landscape of Clinical, Immune, and Molecular Features in Non-Metastatic Rectal Cancer
Soledad Iseas, Juan M. Sendoya, Juan Robbio, Mariana Coraglio, Mirta Kujaruk, Vanesa Mikolaitis, Mariana Rizzolo, Ana Cabanne, Gonzalo Ruiz, Rubén Salanova, Ubaldo Gualdrini, Guillermo Méndez, Marina Antelo, Marcela Carballido, Cecilia Rotondaro, Julieta
Frontiers in Oncology.2022;[Epub] CrossRef
Carcinoembryonic Antigen, the Most Accessible Test for Predicting Colorectal Cancer Prognosis: Exploring Alternative Roles
Sanghee Kang
Annals of Coloproctology.2021; 37(3): 129. CrossRef

Role of β₁-Integrin in Colorectal Cancer: Case-Control Study: Bo-Young Oh, Kwang Ho Kim, Soon Sup Chung, Kyoung Sook Hong, Ryung-Ah Lee; Ann Coloproctol. 2014;30(2):61-70. Published online April 25, 2014; DOI: https://doi.org/10.3393/ac.2014.30.2.61

4,538 View
33 Download
12 Web of Science
12 Citations

Abstract PDF

Purpose

In the metastatic process, interactions between circulating tumor cells (CTCs) and the extracellular matrix or surrounding cells are required. β₁-Integrin may mediate these interactions. The aim of this study was to investigate whether β₁-integrin is associated with the detection of CTCs in colorectal cancer.

Methods

We enrolled 30 patients with colorectal cancer (experimental group) and 30 patients with benign diseases (control group). Blood samples were obtained from each group, carcinoembryonic antigen (CEA) mRNA for CTCs marker and β₁-integrin mRNA levels were estimated by using reverse transcription-polymerase chain reaction, and the results were compared between the two groups. In the experimental group, preoperative results were compared with postoperative results for each marker. In addition, we analyzed the correlation between the expressions of β₁-integrin and CEA.

Results

CEA mRNA was detected more frequently in colorectal cancer patients than in control patients (P = 0.008). CEA mRNA was significantly reduced after surgery in the colorectal cancer patients (P = 0.032). β₁-Integrin mRNA was detected more in colorectal cancer patients than in the patients with benign diseases (P < 0.001). In colorectal cancer patients, expression of β₁-integrin mRNA was detected more for advanced-stage cancer than for early-stage cancer (P = 0.033) and was significantly decreased after surgery (P < 0.001). In addition, expression of β₁-integrin mRNA was significantly associated with that of CEA mRNA in colorectal cancer patients (P = 0.001).

Conclusion

In conclusion, β₁-integrin is a potential factor for forming a prognosis following surgical resection in colorectal cancer patients. β₁-Integrin may be a candidate for use as a marker for early detection of micrometastatic tumor cells and for monitoring the therapeutic response in colorectal cancer patients.

Citations

Citations to this article as recorded by

A review on mechanobiology of cell adhesion networks in different stages of sporadic colorectal cancer to explain its tumorigenesis
Siti Hawa Ngalim, Norwahida Yusoff, Rayzel Renitha Johnson, Siti Razila Abdul Razak, Xinyue Chen, Jamie K. Hobbs, Yeong Yeh Lee
Progress in Biophysics and Molecular Biology.2022; 175: 63. CrossRef
The Expression Pattern of Adhesion G Protein-Coupled Receptor F5 Is Related to Cell Adhesion and Metastatic Pathways in Colorectal Cancer—Comprehensive Study Based on In Silico Analysis
Huining Kang, Jakub Fichna, Ksenia Matlawska-Wasowska, Damian Jacenik
Cells.2022; 11(23): 3876. CrossRef
Functional Interplay Between Collagen Network and Cell Behavior Within Tumor Microenvironment in Colorectal Cancer
Cuong Cao Le, Amar Bennasroune, Benoit Langlois, Stéphanie Salesse, Camille Boulagnon-Rombi, Hamid Morjani, Stéphane Dedieu, Aline Appert-Collin
Frontiers in Oncology.2020;[Epub] CrossRef
CRISPR/Cas9 in Cancer Immunotherapy: Animal Models and Human Clinical Trials
Khalil Khalaf, Krzysztof Janowicz, Marta Dyszkiewicz-Konwińska, Greg Hutchings, Claudia Dompe, Lisa Moncrieff, Maurycy Jankowski, Marta Machnik, Urszula Oleksiewicz, Ievgeniia Kocherova, Jim Petitte, Paul Mozdziak, Jamil A. Shibli, Dariusz Iżycki, Małgorz
Genes.2020; 11(8): 921. CrossRef
N-glycosylation-defective splice variants of neuropilin-1 promote metastasis by activating endosomal signals
Xiuping Huang, Qing Ye, Min Chen, Aimin Li, Wenting Mi, Yuxin Fang, Yekaterina Y. Zaytseva, Kathleen L. O’Connor, Craig W. Vander Kooi, Side Liu, Qing-Bai She
Nature Communications.2019;[Epub] CrossRef
Epidermal growth factor-mediated Rab25 pathway regulates integrin β1 trafficking in colon cancer
Kyung Sook Hong, Eun-Young Jeon, Soon Sup Chung, Kwang Ho Kim, Ryung-Ah Lee
Cancer Cell International.2018;[Epub] CrossRef
Animal models of colorectal cancer with liver metastasis
Bo Young Oh, Hye Kyung Hong, Woo Yong Lee, Yong Beom Cho
Cancer Letters.2017; 387: 114. CrossRef
A New Size-based Platform for Circulating Tumor Cell Detection in Colorectal Cancer Patients
Bo Young Oh, Jhingook Kim, Woo Yong Lee, Hee Cheol Kim
Clinical Colorectal Cancer.2017; 16(3): 214. CrossRef
Twist1-induced epithelial-mesenchymal transition according to microsatellite instability status in colon cancer cells
Bo Young Oh, So-Young Kim, Yeo Song Lee, Hye Kyung Hong, Tae Won Kim, Seok Hyung Kim, Woo Yong Lee, Yong Beom Cho
Oncotarget.2016; 7(35): 57066. CrossRef
Expression of L1 protein correlates with cluster of differentiation 24 and integrin β1 expression in gastrointestinal stromal tumors
YUE DU, HAIHONG ZHANG, ZHONGMIN JIANG, GUOWEI HUANG, WENLI LU, HESHENG WANG
Oncology Letters.2015; 9(6): 2595. CrossRef
Correlation between tumor engraftment in patient-derived xenograft models and clinical outcomes in colorectal cancer patients
Bo Young Oh, Woo Yong Lee, Sungwon Jung, Hye Kyung Hong, Do-Hyun Nam, Yoon Ah Park, Jung Wook Huh, Seong Hyeon Yun, Hee Cheol Kim, Ho-Kyung Chun, Yong Beom Cho
Oncotarget.2015; 6(18): 16059. CrossRef
Invasion and Metastasis in the Viewpoint of Cell Adhesive Molecules
Jong-Woo Kim
Annals of Coloproctology.2014; 30(2): 57. CrossRef

Optimal Time of Initiating Adjuvant Chemotherapy After Curative Surgery in Colorectal Cancer Patients: Kyu Min Kang, Kyung Sook Hong, Gyoung Tae Noh, Bo-Young Oh, Soon Sup Chung, Ryung-Ah Lee, Kwang Ho Kim; Ann Coloproctol. 2013;29(4):150-154. Published online August 29, 2013; DOI: https://doi.org/10.3393/ac.2013.29.4.150

5,213 View
40 Download
13 Citations

Abstract PDF

Purpose

Adjuvant chemotherapy is routinely recommended for locally advanced colorectal cancer (CRC). There are very few data for the optimal starting date of adjuvant chemotherapy after the surgery. This study aimed to evaluate the effectiveness of earlier adoption of adjuvant chemotherapy after curative surgery for stage III CRC.

Methods

In this study, 159 patients with stage III CRC, who had undergone a curative resection, were enrolled retrospectively. Patients were categorized into 3 groups representing different timings to initiate the chemotherapy; less than 2 weeks (group 1), 3 to 4 weeks (group 2), and more than 5 weeks (group 3). The overall survival rate (OS) and the relapse-free survival rate (RFS) were analyzed to evaluate the effectiveness of adjuvant chemotherapy.

Results

The 5-year OSs of the patients were 73.7% in group 1, 67.0% in group 2, and 55.2% in group 3. The 5-year RFSs of the patients were 48.8% in group 1, 64.7% in group 2, and 57.1% in group 3. There were no significant differences in either the OS or the RFS (P = 0.200, P = 0.405).

Conclusion

Starting chemotherapy earlier than 6 weeks after surgery does not show any significant difference. Thus, although adjuvant chemotherapy should preferably begin within 6 weeks, the starting date should not necessarily be hastened, and the patient's general condition should be taken into consideration.

Citations

Citations to this article as recorded by

Minimally Invasive Approach Provides Oncological Benefit in Patients with High Risk of Very Early Recurrence (VER) After Surgery for Intrahepatic Cholangiocarcinoma (iCCA)
Francesca Ratti, Cecilia Maina, Lucrezia Clocchiatti, Rebecca Marino, Federica Pedica, Andrea Casadei Gardini, Francesco De Cobelli, Luca Antonio Maria Aldrighetti
Annals of Surgical Oncology.2024; 31(4): 2557. CrossRef
The optimal time of starting adjuvant chemotherapy after curative surgery in patients with colorectal cancer
Yuchong Yang, Yao Lu, Hui Tan, Ming Bai, Xia Wang, Shaohua Ge, Tao Ning, Le Zhang, Jingjing Duan, Yansha Sun, Rui Liu, Hongli Li, Yi Ba, Ting Deng
BMC Cancer.2023;[Epub] CrossRef
Apurinic/apyrimidinic endonuclease 1 is associated with poor prognosis after curative resection followed by adjuvant chemotherapy in patients with stage III colon cancer
Ji Hyeong Song, Myung Sun Lee, Eun Young Cha, Kyung Ha Lee, Ji Yeon Kim, Jin Soo Kim
Korean Journal of Clinical Oncology.2022; 18(1): 1. CrossRef
Impact of the Time Interval Between Primary Debulking Surgery and Start of Adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer
Hao Lin, Wen-Hsin Chen, Chen-Hsuan Wu, Yu-Che Ou, Yu-Jen Chen, Ying-Yi Chen, Yu-Han Lin, Hung-Chun Fu
Cancer Management and Research.2021; Volume 13: 5413. CrossRef
Bevacizumab and erlotinib versus bevacizumab for colorectal cancer treatment: systematic review and meta-analysis
Sara Kaveh, Parvin Ebrahimi, Aziz Rezapour, Masoud Mozafari, Kourosh Sayehmiri
International Journal of Clinical Pharmacy.2019; 41(1): 30. CrossRef
Timing of Adjuvant Chemotherapy and Survival in Colorectal, Gastric, and Pancreatic Cancer. A Systematic Review and Meta-Analysis
Fausto Petrelli, Alberto Zaniboni, Antonio Ghidini, Michele Ghidini, Luca Turati, Claudio Pizzo, Margherita Ratti, Michela Libertini, Gianluca Tomasello
Cancers.2019; 11(4): 550. CrossRef
Safety and feasibility of in-hospital early chemotherapy initiation after surgery in patients with stage II–IV colon cancer
Jeonghyun Kang, Su-Weon Chong, Eun Jung Park, Seung Hyuk Baik, Kang Young Lee
Medicine.2019; 98(18): e15371. CrossRef
Surgical stress response and promotion of metastasis in colorectal cancer: a complex and heterogeneous process
Corina Behrenbruch, Carolyn Shembrey, Sophie Paquet-Fifield, Christina Mølck, Hyun-Jung Cho, Michael Michael, Benjamin N. J. Thomson, Alexander G. Heriot, Frédéric Hollande
Clinical & Experimental Metastasis.2018; 35(4): 333. CrossRef
Intensity modulated radiotherapy delivers competitive local control rate with limited acute toxicity in the adjuvant treatment of rectal cancer
Cheng-Yen Lee, Chih-Chia Chang, Hsin-Yi Yang, Pin-Yi Chiang, Yuk-Wah Tsang
Japanese Journal of Clinical Oncology.2018; 48(7): 653. CrossRef
Molecular analysis of sentinel lymph node in colon carcinomas by one-step nucleic acid amplification (OSNA) reduces time to adjuvant chemotherapy interval
Alix Marhic, Jean-François Tremblay, Rachid Kaci, Thierry André, Clarisse Eveno, Marc Pocard
Digestive and Liver Disease.2017; 49(8): 924. CrossRef
Timely initiation of chemotherapy: a systematic literature review of six priority cancers – results and recommendations for clinical practice
M. Alexander, R. Blum, K. Burbury, J. Coutsouvelis, M. Dooley, O. Fazil, T. Griffiths, H. Ismail, S. Joshi, N. Love, S. Opat, P. Parente, N. Porter, E. Ross, J. Siderov, P. Thomas, S. White, S. Kirsa, D. Rischin
Internal Medicine Journal.2017; 47(1): 16. CrossRef
Association Between Time (Initiation and Length) and Oncological Outcomes for the Patients with Colon Cancer Treated with Adjuvant Chemotherapy
In Seob Jeong, Jong Han Yoo, Sang Hyuk Seo, Min Sung An, Kwang Hee Kim, Ki Beom Bae, Chang Soo Choi, Jin Won Hwang, Ji Hyun Kim, Mi Seon Kang, Min Kyung Oh, Kwan Hee Hong
Indian Journal of Surgery.2015; 77(S3): 1252. CrossRef
Timing of Adjuvant Chemotherapy in Colorectal Cancer Patients
Moo-Jun Baek
Annals of Coloproctology.2013; 29(4): 138. CrossRef

Clinical Applications of Radio-Frequency Ablation in Liver Metastasis of Colorectal Cancer: Ji Hun Gwak, Bo-Young Oh, Ryung Ah Lee, Soon Sup Chung, Kwang Ho Kim; J Korean Soc Coloproctol. 2011;27(4):202-210. Published online August 31, 2011; DOI: https://doi.org/10.3393/jksc.2011.27.4.202

4,469 View
38 Download
10 Citations

Abstract PDF

Purpose

The aim of this study is to evaluate long-term survival and prognostic factors for radio-frequency ablation (RFA) in colorectal liver metastases.

Methods

We retrospectively reviewed 35 colorectal liver metastases patients who underwent RFA between 2004 and 2008. We analyzed survival after RFA and prognostic factors for survival.

Results

Of the 35 patients, 23 patients were male and 12 were female. Their mean age was 62.40 ± 12.52 years. Mean overall survival was 38.8 ± 4.6 months, and mean progression free survival was 19.9 ± 3.4 months. Three- and 5-year overall survival rates were 42.7 ± 0.1% and 26.0 ± 0.1%, respectively. Three- and 5-year progression-free survival rates were 19.6 ± 0.1% and 4.9 ± 0.04%, respectively. Overall survival and progression-free survival were significantly improved in male and in patients with carcinoembryonic antigen (CEA) ≤ 100 ng/mL, carbohydrate antigen (CA) 19-9 ≤ 100 ng/mL, absence of extrahepatic disease, and a unilobar hepatic lesion. In addition, progression-free survival was improved in patients with a solitary hepatic lesion. On the multivariate analysis, significant survival factors were the absence of extrahepatic disease and the presence of a unilobar hepatic lesion.

Conclusion

RFA for colorectal liver metastases is an effective treatment option in male patients and in patients with CEA or CA19-9 ≤ 100, absence of extrahepatic disease, a solitary hepatic lesion, and a unilobar hepatic lesion.

Citations

Citations to this article as recorded by

The combined detection of carcinoembryonic antigen, carcinogenic antigen 125, and carcinogenic antigen 19-9 in colorectal cancer patients
Ling-Zhen Gong, Qian-Wen Wang, Jie-Wen Zhu
World Journal of Gastrointestinal Surgery.2024; 16(7): 2073. CrossRef
Microwave Ablation, Radiofrequency Ablation, Irreversible Electroporation, and Stereotactic Ablative Body Radiotherapy for Intermediate Size (3–5 cm) Unresectable Colorectal Liver Metastases: a Systematic Review and Meta-analysis
Sanne Nieuwenhuizen, Madelon Dijkstra, Robbert S. Puijk, Bart Geboers, Alette H. Ruarus, Evelien A. Schouten, Karin Nielsen, Jan J. J. de Vries, Anna M. E. Bruynzeel, Hester J. Scheffer, M. Petrousjka van den Tol, Cornelis J. A. Haasbeek, Martijn R. Meije
Current Oncology Reports.2022; 24(6): 793. CrossRef
Optimizing Loco Regional Management of Oligometastatic Colorectal Cancer: Technical Aspects and Biomarkers, Two Sides of the Same Coin
Giovanni Mauri, Lorenzo Monfardini, Andrea Garnero, Maria Giulia Zampino, Franco Orsi, Paolo Della Vigna, Guido Bonomo, Gianluca Maria Varano, Marco Busso, Carlo Gazzera, Paolo Fonio, Andrea Veltri, Marco Calandri
Cancers.2021; 13(11): 2617. CrossRef
Combined CT-guided radiofrequency ablation with systemic chemotherapy improves the survival for nasopharyngeal carcinoma with oligometastasis in liver: Propensity score matching analysis
Wang Li, Yutong Bai, Ming Wu, Lujun Shen, Feng Shi, Xuqi Sun, Caijin Lin, Boyang Chang, Changchuan Pan, Zhiwen Li, Peihong Wu
Oncotarget.2017; 8(32): 52132. CrossRef
Radiofrequency ablation in combined treatment of metastatic colorectal liver cancer
O. G. Skipenko, K. N. Petrenko, N. N. Bagmet, A. L. Bedzhanyan, L. O. Polishchuk, N. K. Chardarov, G. A. Shatveryan
Khirurgiya. Zhurnal im. N.I. Pirogova.2016; (12): 4. CrossRef
Systematic review of 12 years of thermal ablative therapies of non-resectable colorectal cancer liver metastases
Sameh Saif, Ania Z, Kielar, Matthew McInnes
International Journal of Gastrointestinal Intervention.2016; 5(1): 27. CrossRef
Evaluation of YO-PRO-1 as an early marker of apoptosis following radiofrequency ablation of colon cancer liver metastases
Sho Fujisawa, Yevgeniy Romin, Afsar Barlas, Lydia M. Petrovic, Mesruh Turkekul, Ning Fan, Ke Xu, Alessandra R. Garcia, Sebastien Monette, David S. Klimstra, Joseph P. Erinjeri, Stephen B. Solomon, Katia Manova-Todorova, Constantinos T. Sofocleous
Cytotechnology.2014; 66(2): 259. CrossRef
Clinical outcome of ultrasound-guided percutaneous microwave ablation on colorectal liver metastases
JIANBIN WANG, PING LIANG, JIE YU, MING-AN YU, FANGYI LIU, ZHIGANG CHENG, XIAOLING YU
Oncology Letters.2014; 8(1): 323. CrossRef
Efficacy and safety of thermal ablation in patients with liver metastases
Yingjun Liu, Shengping Li, Xiangbin Wan, Yi Li, Binkui Li, Yaqi Zhang, Yunfei Yuan, Yun Zheng
European Journal of Gastroenterology & Hepatology.2013; 25(4): 442. CrossRef
Gastric perforation following stereotactic body radiation therapy of hepatic metastasis from colon cancer
Matthew J. Furman, Giles F. Whalen, Shimul A. Shah, Sidney P. Kadish
Practical Radiation Oncology.2013; 3(1): 40. CrossRef

Epidermal Growth Factor Receptor Mutations in Colorectal Cancer Patients: Bo-Young Oh, Ryung-Ah Lee, Soon-Sup Chung, Kwang Ho Kim; J Korean Soc Coloproctol. 2011;27(3):127-132. Published online June 30, 2011; DOI: https://doi.org/10.3393/jksc.2011.27.3.127

3,887 View
38 Download
15 Citations

Abstract PDF

Purpose

The epidermal growth factor receptor (EGFR) plays an important role in tumorigenesis and tumor progression of colorectal cancer and leads to the activation of intracellular signaling pathways. The use of anti-EGFR-targeted therapy has increased for patients with colorectal cancer, but patients with EGFR mutations will be resistant to anti-EGFR-targeted therapy. The identification of gene mutations is critical in cancer treatment; therefore, the aim of this study is to investigate the incidences of EGFR mutations in colorectal cancer patients in Korea.

Methods

We retrospectively reviewed 58 colorectal cancer patients who underwent surgery between 2003 and 2006. We analyzed their EGFR mutations in four loci by DNA sequencing. In addition, we analyzed the correlation between the presence of EGFR mutation and patients' clinicopathologic features.

Results

Of the 58 patients, 35 patients were male and 23 were female. Their mean age was 63.28 ± 11.18 years. Two patients (3.45%) were diagnosed as stage Tis, 7 patients (12.07%) as stage I, 24 patients (41.38%) as stage II, 20 patients (34.48%) as stage III, and 5 patients (8.62%) as stage IV. As a result of mutational analysis, EGFR mutations on exon 20 were detected in 13 patients (22.41%, G→A transitions). No EGFR mutations were detected on exons 18, 19, and 21. EGFR mutation was increased in the earlier stage and in the absence of lymph node metastasis (P = 0.028).

Conclusion

The incidence of EGFR mutation in Korean colorectal cancer patients is 22.41%. In addition, EGFR mutation was significantly increased in the earlier stage and in the absence of lymph node metastasis.

Citations

Citations to this article as recorded by

Identification of potential inhibitors for drug-resistant EGFR mutations in non-small cell lung cancer using whole exome sequencing data
Nagasundaram Nagarajan, Chittibabu Guda
Frontiers in Pharmacology.2024;[Epub] CrossRef
Analysis of EGFR binding hotspots for design of new EGFR inhibitory biologics
Claiborne W. Tydings, Bhuminder Singh, Adam W. Smith, Kaitlyn V. Ledwitch, Benjamin P. Brown, Christine M. Lovly, Allison S. Walker, Jens Meiler
Protein Science.2024;[Epub] CrossRef
Gut-associated lymphoid tissue carcinoma analyzed using next-generation sequencing: A case report
Naomi Sato, Sadahide Ono, Kurodo Kamiya, Noriyuki Uesugi, Fumiyoshi Fujishima, Hiroshi Kawachi, Tamotsu Sugai
Pathology - Research and Practice.2024; 263: 155621. CrossRef
Diatom-Based Nanomedicine for Colorectal Cancer Treatment: New Approaches for Old Challenges
Chiara Tramontano, Luca De Stefano, Ilaria Rea
Marine Drugs.2023; 21(5): 266. CrossRef
Pharmacophore-Based Virtual Screening and In-Silico Explorations of Biomolecules (Curcumin Derivatives) of Curcuma longa as Potential Lead Inhibitors of ERBB and VEGFR-2 for the Treatment of Colorectal Cancer
Syeda Abida Ejaz, Mubashir Aziz, Mohamed Fawzy Ramadan, Ammara Fayyaz, Muhammad Sajjad Bilal
Molecules.2023; 28(10): 4044. CrossRef
Cutaneous adverse reactions resulting from targeted cancer therapies: histopathologic and clinical findings
Dylan Haynes, Eric E. Morgan, Emily Y. Chu
Human Pathology.2023; 140: 129. CrossRef
Genomic landscape of locally advanced rectal adenocarcinoma: Comparison between before and after neoadjuvant chemoradiation and effects of genetic biomarkers on clinical outcomes and tumor response
Tae Hoon Lee, Bum‐Sup Jang, Ji Hyun Chang, Eunji Kim, Jeong Hwan Park, Eui Kyu Chie
Cancer Medicine.2023; 12(14): 15664. CrossRef
Targeted Therapies in Colorectal Cancer: Recent Advances in Biomarkers, Landmark Trials, and Future Perspectives
Joao Manzi, Camilla O. Hoff, Raphaella Ferreira, Agustin Pimentel, Jashodeep Datta, Alan S. Livingstone, Rodrigo Vianna, Phillipe Abreu
Cancers.2023; 15(11): 3023. CrossRef
NRAS mutant E132K identified in young-onset sporadic colorectal cancer and the canonical mutants G12D and Q61K affect distinct oncogenic phenotypes
Ryan Timothy D. Yu, Reynaldo L. Garcia
Scientific Reports.2020;[Epub] CrossRef
Predicting Response to Neoadjuvant Therapy in Colorectal Cancer Patients the Role of Messenger-and Micro-RNA Profiling
Alberto Izzotti, Chiara Ceccaroli, Marta Geretto, Filippo Grillo Ruggieri, Sara Schenone, Emilio Di Maria
Cancers.2020; 12(6): 1652. CrossRef
Impact of RAS mutation subtype on clinical outcome—a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer
Marcel Wiesweg, Stefan Kasper, Karl Worm, Thomas Herold, Henning Reis, Linda Sara, Martin Metzenmacher, Annalena Abendroth, Kaid Darwiche, Clemens Aigner, Heiner H. Wedemeyer, Fabian A. Helfritz, Martin Stuschke, Brigitte Schumacher, Peter Markus, Andreas
Oncogene.2019; 38(16): 2953. CrossRef
Co-targeting of EGFR and autophagy signaling is an emerging treatment strategy in metastatic colorectal cancer
Evangelos Koustas, Michalis V. Karamouzis, Chrysovalantou Mihailidou, Dimitrios Schizas, Athanasios G. Papavassiliou
Cancer Letters.2017; 396: 94. CrossRef
Lack of Mutations in Protein Tyrosine Kinase Domain Coding Exons 19 and 21 of the EGFR Gene in Oral Squamous Cell Carcinomas
Dhaval Tushar Mehta, Thangavelu Annamalai, Arvind Ramanathan
Asian Pacific Journal of Cancer Prevention.2014; 15(11): 4623. CrossRef
Anti-epidermal growth factor receptor therapy for advanced head and neck squamous cell carcinoma: a meta-analysis
Shoude Zhang, Jia Chen, Hua Jiang, Haina Ma, Beibei Yang
European Journal of Clinical Pharmacology.2012; 68(5): 561. CrossRef
Are Mutations of the EGFR Gene Promising Predictive Markers for Anti-EGFR mAbs in Colorectal Carcinomas?
Dong-Guk Park
Journal of the Korean Society of Coloproctology.2011; 27(3): 103. CrossRef

First
Prev
Page of 1
Next
Last

Search